Journal article · 2026 · Open access
HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial
JAMA · Published 11 November 2026 · DOI 10.1001/jama.2026.19809
In brief
“HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial” is a 2026 journal article by Sascha N. Goonewardena and 6 co-authors, published in JAMA. OpenAlex counts 1 citations as of 18 November 2026. It is open access: the full text is free to read at PubMed Central.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 0.98
- References
- 25
- Authors
- 7
Abstract
Importance: Current treatments approved by the US Food and Drug Administration for internal actinide contamination (pentetate calcium trisodium and pentetate zinc trisodium) require intravenous injection or nebulized inhalation under medical supervision and have limited radionuclide coverage. HOPO 14-1, an oral form of 3,4,3-LI(1,2-HOPO), is the first shelf-stable, broad-spectrum actinide chelator in clinical development that does not require intravenous access or trained personnel. In preclinical models, 3,4,3-LI(1,2-HOPO) removed a broad range of actinides, and its oral route supports scalable emergency medical use. Objective: To evaluate the safety, tolerability, pharmacokinetic parameters, and excretion of a single dose of HOPO 14-1 in healthy adults. Design, Setting, and Participants: This was a phase 1 nonrandomized clinical trial including 42 healthy adults (6 per dose level) with evaluations for 14 days after administration of a single dose and conducted at a single site in the US. Participants were recruited and screened between March 2023 and July 2025 and follow-up was completed in August 2025. Intervention: Single oral dose of HOPO 14-1 administered at 1 of 7 dose levels (100 mg, 200 mg, 500 mg, 1200 mg, 2500 mg, 5000 mg, or 7500 mg) with follow-up through day 14 after dose administration. Main Outcomes and Measures: The primary outcomes were the incidence and severity of adverse events, drug-related adverse events, and serious adverse events. The secondary outcomes were plasma pharmacokinetic parameters and cumulative urinary and fecal excretion. Results: Of the 42 healthy adults enrolled (median age, 43 [IQR, 34-51] years; 64% female), all received a single dose of HOPO 14-1 (administered across all dose levels as assigned). There were no serious adverse events or dose-limiting toxic effects. The drug-related adverse events included diarrhea (31%), vomiting (14%), headache (12%), and fatigue (7%); all were mild to moderate in severity. Gastrointestinal adverse events were the principal tolerability findings and most evident at the highest doses. The plasma pharmacokinetic parameters demonstrated rapid absorption (median time of maximum plasma concentration, 0.86 [range, 0.53-1.60] hours to 1.90 [range, 1.40-2.90] hours) and dose-dependent increases in systemic exposure, with greater than proportional increases at higher doses. Fecal excretion was the primary route of elimination; urinary excretion was minimal. Conclusions and Relevance: Single oral doses of HOPO 14-1 up to 7500 mg were administered without dose-limiting toxicity or serious adverse events in healthy adults. Gastrointestinal tolerability defined the practical single-dose ceiling. These findings establish the first human safety and pharmacokinetic profile of a novel, orally administered actinide chelator and support further clinical evaluation of HOPO 14-1 as a countermeasure for internal radionuclide and heavy…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Goonewardena, S. N., Atleski, L., Bunin, D. I., Furimsky, A. M., Pui, S., Green, C. E., & Chang, P. Y. (2026). HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.19809
MLA 9
Goonewardena, Sascha N., et al. “HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial.” JAMA, 2026. https://doi.org/10.1001/jama.2026.19809.
Chicago
Goonewardena, Sascha N., Laura Atleski, Deborah I. Bunin, Anna M. Furimsky, Sandra Pui, Carol E. Green, and Polly Y. Chang. 2026. “HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial.” JAMA. https://doi.org/10.1001/jama.2026.19809.
Harvard
Goonewardena, S. N. et al. (2026) ‘HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial’, JAMA. doi:10.1001/jama.2026.19809.
IEEE
S. N. Goonewardena et al., “HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial,” JAMA, 2026, doi: 10.1001/jama.2026.19809.
BibTeX
@article{goonewardena2026hopo,
title = {{HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial}},
author = {Goonewardena, Sascha N. and Atleski, Laura and Bunin, Deborah I. and Furimsky, Anna M. and Pui, Sandra and Green, Carol E. and Chang, Polly Y.},
journal = {JAMA},
year = {2026},
doi = {10.1001/jama.2026.19809},
url = {https://doi.org/10.1001/jama.2026.19809}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Physical Sciences › Chemistry › Inorganic Chemistry › Radioactive element chemistry and processing
- oral administration
- pharmacokinetics
- drug safety and tolerability
- urinary and fecal excretion
- dose-limiting toxicity
- gastrointestinal adverse effects
- radionuclide removal
- emergency medical response
Work with this paper
Most-cited papers in Chemistry
- CRC Handbook of Chemistry and PhysicsW.M. Haynes · CRC Press eBooks · 2014 · 58,210 citations
- Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.Harry Towbin, Th. Staehelin, J Gordon · Proceedings of the National Academy of Sciences · 1979 · 53,242 citations
- Crystal structure refinement with SHELXLGeorge M. Sheldrick · Acta Crystallographica Section C Structural Chemistry · 2014 · 45,305 citations
- Comparison of simple potential functions for simulating liquid waterWilliam L. Jorgensen, Jayaraman Chandrasekhar, Jeffry D. Madura and 2 more · The Journal of Chemical Physics · 1983 · 41,735 citations
- Equation of State Calculations by Fast Computing MachinesN. Metropolis, Arianna W. Rosenbluth, M. N. Rosenbluth and 2 more · The Journal of Chemical Physics · 1953 · 38,111 citations
Questions about this paper
How do I cite this paper in APA style?
Goonewardena, S. N., Atleski, L., Bunin, D. I., Furimsky, A. M., Pui, S., Green, C. E., & Chang, P. Y. (2026). HOPO 14-1, an Oral Actinide Chelator: A Phase 1 Nonrandomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2026.19809
How many times has this paper been cited?
1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Sascha N. Goonewardena, Laura Atleski, Deborah I. Bunin, Anna M. Furimsky, Sandra Pui, Carol E. Green, Polly Y. Chang.
What is the DOI of this paper?
10.1001/jama.2026.19809, permanently at https://doi.org/10.1001/jama.2026.19809. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.